Welcome to our dedicated page for Navidea Biopharm news (Ticker: NAVB), a resource for investors and traders seeking the latest updates and insights on Navidea Biopharm stock.
Navidea Biopharmaceuticals, Inc. reports developments tied to its biopharmaceutical platform, corporate status, and capital structure. The company focuses on precision immunodiagnostic agents and immunotherapeutics built around the Manocept platform, which targets the CD206 mannose receptor expressed on activated macrophages. Its disclosed programs include Tc99m tilmanocept and clinical work in rheumatoid arthritis, along with a stated focus on therapeutic assets.
Navidea news also covers Chapter 11, Subchapter V bankruptcy proceedings, OTC trading status, voluntary SEC deregistration actions, reverse stock split authority, Section 382 rights plan matters related to tax assets, litigation settlements, special stockholder meetings, and board changes. These updates place the company’s product-development strategy alongside recurring disclosure themes involving governance, financing, reporting obligations, and corporate restructuring.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) announced its participation in the 2021 ICR Conference on January 14, 2021, at 2:30 p.m. EST. The conference will feature CEO Jed Latkin and CBO Joel Kaufman. A live video webcast of the presentation will be available, and a replay will be accessible for one year. Navidea focuses on developing precision immunodiagnostic agents via its Manocept™ platform, designed to enhance patient care and improve diagnostic accuracy. For more information, visit www.navidea.com.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) announced the appointment of Malcolm G. Witter to its Board of Directors. With decades of experience in financial and corporate governance, Witter currently leads corporate development at USI Insurance Services. He has held positions at Bear Stearns, EF Hutton, and Dean Witter, and earned his MBA from Stanford. CEO Jed Latkin expressed confidence in Witter's expertise in M&A and corporate finance to help guide the company in its future developments.
Navidea Biopharmaceuticals (NYSE American: NAVB) announced the full enrollment of its NAV3-31 Phase 2B study, evaluating Tc99m tilmanocept imaging for rheumatoid arthritis (RA) patients. The three-arm trial includes healthy subjects and RA patients, assessing treatment efficacy indicators. Interim results support the imaging's predictive capabilities. The company plans to finalize the Phase 3 study design with the FDA while maintaining trial momentum. RA affects over 1.3 million Americans, and successful product development could significantly impact patient management.